ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...
RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) based on preliminary clinical ...
Detailed price information for Wave Life Sci Ord Sh (WVE-Q) from The Globe and Mail including charting and trades.
Chonnam National University has once again solidified its international reputation as Korea's leading institution in "nano-regenerative medicine" ...
The publication, titled “Prime Editing for p47-phox Chronic Granulomatous Disease,” reports initial data for two patients treated in the Phase 1/2 trial of PM359, which was designed to assess safety, ...
The company’s chief medical officer discusses its trajectory with the blockbuster Brukinsa and its strong hematology pipeline.
5d
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a ...
Cedars-Sinai scientists have developed an experimental drug that repairs DNA and serves as a prototype for a new class of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback